The Cigna Group
CI
$278.51
+1.51%
The Cigna Group is a diversified healthcare enterprise operating two primary platforms: Cigna Healthcare, which provides medical insurance and benefits management (largely through self-funded employer arrangements), and Evernorth, a pharmacy benefit management and specialty pharmacy services business significantly expanded by the 2018 acquisition of Express Scripts. The company is a dominant player in the U.S. healthcare landscape, with Evernorth serving as a key intermediary between drug manufacturers, pharmacies, and payers, while Cigna Healthcare covers approximately 16 million U.S. medical members and 2 million international members. The current investor narrative centers on Cigna's strategic pivot to sharpen its focus on core growth engines, including the recent decision to exit the individual exchange business and a strategic review of its eviCore subsidiary, alongside raised full-year guidance. However, the stock has faced pressure from broader sector headwinds, including persistent reimbursement pressures and regulatory scrutiny, as reflected in recent analyst downgrades and underperformance relative to the S&P 500.…
CI
The Cigna Group
$278.51
Related headlines
Investment Opinion: Should I buy CI Today?
The synthesized recommendation is Hold, with a bias toward accumulation on weakness. The core thesis is that CI is deeply undervalued (forward PE of 8.08, PEG of 0.15) with a 26.5% upside to the average analyst target of $342.29, but near-term headwinds and recent downgrades warrant caution. The consensus rating is Buy (1.75), yet the stock's 8.91% one-year decline and negative relative strength suggest the market is pricing in unresolved risks.
Supporting evidence includes: 1) Revenue growth of 6.6% YoY in Q2 2026, driven by Evernorth; 2) TTM free cash flow of $9.11 billion, supporting a 2.20% dividend yield and 27% payout ratio; 3) A forward PE of 8.08, which is less than half the S&P 500's average and near the low end of CI's historical range (10–33); 4) Analyst targets ranging from $288 to $400, with even the low end implying a 6.5% gain. The stock's PS ratio of 0.27 is also near historical lows.
Key risks that could invalidate the thesis include: 1) Continued margin compression if reimbursement pressures accelerate, as net margin is only 2.32%; 2) Execution risk from the strategic pivot (exit from individual exchanges, eviCore review); 3) Regulatory intervention in PBM pricing. The rating would upgrade to Buy if CI demonstrates margin stabilization (e.g., operating margin holding above 4%) or if the stock breaks above $300 with volume. It would downgrade to Sell if revenue growth decelerates below 3% or if free cash flow turns negative for two consecutive quarters. Relative to its history and peers, CI appears undervalued, but the discount reflects legitimate concerns.
Sign up to view all
CI 12-Month Price Forecast
CI presents a classic value trap versus deep value debate. The stock is statistically cheap (PEG 0.15, PS 0.27) and offers a 26.5% upside to analyst targets, but it has consistently underperformed the market due to margin pressures and regulatory overhangs. The low beta of 0.317 makes it a defensive holding, but the lack of a near-term catalyst could keep it range-bound. I would upgrade to bullish if CI shows two consecutive quarters of margin expansion and positive operating cash flow. I would downgrade to bearish if revenue growth falls below 3% or if free cash flow turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $342.29 and implied upside of +22.9% versus the current price.
Average Target
$342.29
0 analysts
Implied Upside
+22.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$288 - $400
Analyst target range
Cigna is covered by 24 analysts, with a consensus recommendation of "Buy" (mean rating of 1.75 on a scale where 1 is Strong Buy and 5 is Sell). The average target price is $342.29, implying an upside of approximately 26.5% from the current price of $270.53. This consensus leans bullish, suggesting that analysts see significant value in the stock despite recent underperformance. The high target of $400.00 would represent a 47.9% upside, while the low target of $288.00 still implies a 6.5% gain, indicating that even the most conservative analysts expect positive returns.
The wide target range ($288 to $400) signals high uncertainty, with the high target likely assuming successful execution of strategic initiatives, margin expansion, and multiple expansion, while the low target may price in continued reimbursement pressures and competitive challenges. Recent institutional ratings show a mix of actions: Jefferies downgraded from Buy to Hold on August 4, 2026, while Raymond James downgraded from Strong Buy to Outperform on August 3, 2026, indicating some caution. However, Guggenheim maintained a Buy rating, and Bernstein reiterated an Outperform, suggesting that opinions are divided. The estimated EPS average of $46.74 for the upcoming year, if achieved, would represent a significant increase from the trailing EPS of $0.08, highlighting the potential for earnings growth that could drive the stock higher.
Bulls vs Bears: CI Investment Factors
The bear case currently has stronger evidence due to CI's persistent underperformance (-8.91% 1-year return vs. S&P 500's +15.01%), recent analyst downgrades, and thin margins. However, the bull case is underpinned by an extremely low forward PE of 8.08, a 26.5% analyst target upside, and robust $9.11 billion free cash flow. The most critical tension is whether the market's deep pessimism—reflected in a PEG of 0.15—is overdone or justified by structural headwinds in healthcare reimbursement. If CI can stabilize margins and execute its strategic pivot, the valuation gap could close; otherwise, the downtrend may continue.
Bullish
- Deep valuation discount: CI trades at a trailing PE of 12.34 and a forward PE of just 8.08, well below the broader market and its own historical range of 10–33. The PEG ratio of 0.15 suggests the stock is priced for minimal growth despite a 6.6% YoY revenue increase.
- Strong analyst upside: The 24-analyst consensus is Buy (mean 1.75) with an average target of $342.29, implying 26.5% upside from $270.53. Even the lowest target of $288.00 offers a 6.5% gain, indicating a positive skew.
- Robust free cash flow: TTM free cash flow is $9.11 billion, providing ample capacity for dividends (2.20% yield, 27% payout) and buybacks. This financial flexibility supports shareholder returns even amid margin pressure.
- Consistent revenue growth: Q2 2026 revenue rose 6.6% YoY to $71.67 billion, driven by Evernorth's $61.47 billion. The company has demonstrated steady top-line expansion, with quarterly revenues climbing from $65.50 billion in Q1 2025.
Bearish
- Severe relative underperformance: CI has declined 8.91% over the past year while the S&P 500 gained 15.01%, a relative strength of -23.92%. The 1-month relative strength of -4.94% shows the downtrend is accelerating.
- Thin margins and profitability: Net margin is only 2.32% and operating margin 3.73%, typical for a PBM-heavy model but vulnerable to reimbursement pressure. Gross margin fell to 20.88% in Q2 2026 from 11.73% a year earlier? Actually Q2 2025 gross margin was 11.73%, so it improved, but still low.
- Recent analyst downgrades: Jefferies downgraded CI from Buy to Hold on August 4, 2026, and Raymond James downgraded from Strong Buy to Outperform on August 3, 2026. These actions reflect growing caution about execution and sector headwinds.
- Liquidity concerns: The current ratio of 0.85 indicates current liabilities exceed current assets, signaling potential short-term liquidity tightness. This could constrain flexibility if working capital swings persist.
CI Technical Analysis
Cigna's stock is in a sustained downtrend, with a 1-year price change of -8.91% and a 6-month change of just +0.19%, indicating a lack of positive momentum. The current price of $270.53 sits at approximately 40.8% of its 52-week range (low of $239.51, high of $315.47), suggesting the stock is closer to its lows than highs and may be in a value zone or a falling knife scenario. This positioning implies that the market is pricing in significant headwinds, and a reversal would require a catalyst to shift sentiment.
Recent momentum has been negative, with a 1-month decline of -4.35% and a 3-month decline of -5.99%, both underperforming the S&P 500's respective gains of +0.59% and +3.34%. The relative strength over the past month is -4.94%, indicating significant weakness versus the broader market. This divergence from the longer-term trend (which is also negative) suggests that the downtrend is intact and accelerating, with no clear signs of a near-term bottom. The stock's beta of 0.317 indicates low volatility relative to the market, which may appeal to risk-averse investors but also means it may lag in a strong bull market.
Key technical levels to watch include support at the 52-week low of $239.51, which, if broken, could signal further downside and a potential capitulation. Resistance is at the 52-week high of $315.47, and a breakout above this level would require a significant shift in fundamentals or sentiment. The low beta of 0.317 suggests the stock is less volatile than the market, which could be attractive for conservative portfolios but may limit upside in a rally. The current price is 12.9% above the 52-week low and 14.2% below the 52-week high, indicating a relatively narrow trading range and potential for mean reversion.
Beta
0.30
0.30x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$240-$312
Price range past year
Annual Return
-9.3%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | -1.4% | +0.9% |
| 3m | -4.6% | +3.4% |
| 6m | +2.7% | +14.4% |
| 1y | -9.3% | +16.2% |
| ytd | -0.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory remains solid, with Q2 2026 revenue of $71.67 billion representing a 6.6% year-over-year increase from $67.23 billion in Q2 2025. The company has demonstrated consistent top-line growth, with quarterly revenues rising from $65.50 billion in Q1 2025 to $71.67 billion in Q2 2026. This growth is primarily driven by the Evernorth segment, which generated $61.47 billion in revenue, dwarfing the $11.84 billion from Cigna Healthcare. The steady revenue growth, coupled with raised guidance, suggests that the core business remains resilient despite strategic exits from non-core areas.
Profitability is positive but thin, with a net income of $1.66 billion in Q2 2026 and a net margin of 2.32%. The gross margin for the quarter was 20.88%, which is relatively low for the healthcare sector but typical for a PBM-heavy business model. Operating margin stood at 3.73%, and EBITDA was $2.61 billion, reflecting a 3.65% EBITDA margin. The company's ROE of 14.28% and ROA of 4.46% indicate efficient use of equity but lower asset efficiency, which is common in the insurance industry. Margins have been relatively stable, with slight fluctuations due to seasonality and business mix.
Cigna's balance sheet shows a debt-to-equity ratio of 0.75, which is manageable but indicates moderate leverage. The current ratio of 0.85 suggests potential liquidity tightness, as current liabilities exceed current assets. Free cash flow for the trailing twelve months was $9.11 billion, providing ample capacity to fund operations, dividends, and share repurchases. The company generated $1.13 billion in operating cash flow in Q1 2026 but had a negative $421 million in Q2 2026, largely due to working capital swings. With a dividend yield of 2.20% and a payout ratio of 27.04%, Cigna returns capital to shareholders while retaining earnings for growth.
Quarterly Revenue
$71.7B
2026-06
Revenue YoY Growth
+6.6%
YoY Comparison
Gross Margin
20.9%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given that Cigna is profitable with a trailing net income of $1.66 billion in Q2 2026, the PE ratio is the primary valuation metric. The trailing PE is 12.34, while the forward PE is 8.08, indicating that the market expects significant earnings growth in the coming year. This large gap between trailing and forward PE suggests that analysts anticipate a substantial increase in net income, likely driven by operational efficiencies and strategic initiatives. The PEG ratio of 0.15 is exceptionally low, implying that the stock is undervalued relative to its expected growth rate.
Compared to the healthcare sector, Cigna trades at a discount. The industry average PE for healthcare plans is not provided, but the stock's PS ratio of 0.27 is well below the sector's typical range, and its EV/EBITDA of 8.36 is also low. The forward PE of 8.08 is significantly below the market average, suggesting that Cigna is undervalued relative to its earnings potential. This discount may be justified by the company's lower growth prospects compared to high-flying healthcare technology firms, but it also presents a value opportunity for investors seeking stable cash flows.
Historically, Cigna's PE ratio has ranged from around 10 to 33 over the past few years, with the current trailing PE of 12.34 near the lower end of that range. The PS ratio of 0.27 is also near historical lows, compared to levels above 1.0 in previous years. This suggests that the stock is trading at a valuation discount relative to its own history, which could indicate a value opportunity or reflect concerns about future growth. The low PEG ratio further supports the notion that the market may be undervaluing Cigna's earnings growth potential.
PE
12.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. CI carries a debt-to-equity ratio of 0.75, which is manageable but adds interest expense of $356 million per quarter. The current ratio of 0.85 signals potential liquidity tightness, and operating cash flow turned negative at -$421 million in Q2 2026 due to working capital swings. Net margin is thin at 2.32%, leaving little buffer if reimbursement pressures intensify or medical costs rise. Additionally, revenue is heavily concentrated in the Evernorth segment ($61.47 billion of $71.67 billion), making the company vulnerable to changes in PBM regulation or contract losses.
Market and competitive risks are significant. CI trades at a discount to peers, but this could persist if the market continues to de-rate healthcare plans amid regulatory scrutiny. The stock's beta of 0.317 indicates low volatility, but it has underperformed the S&P 500 by 23.92% over the past year, highlighting sector rotation risk. Recent news of reimbursement pressures and regulatory challenges, as noted in CVS coverage, applies broadly to PBMs. Competitive threats from UnitedHealth's Optum and CVS Caremark could pressure Evernorth's margins. Furthermore, the strategic review of eviCore and exit from individual exchanges may cede market share to competitors.
The worst-case scenario involves a combination of regulatory intervention on PBM pricing, loss of a major contract (e.g., the Department of Defense), and a failure to achieve projected EPS growth. In this scenario, the stock could retest its 52-week low of $239.51, representing a 11.5% decline from the current price of $270.53. If the low analyst target of $288 is breached due to earnings misses, the downside could extend to the $230–$240 range, implying a loss of 11–15%. The maximum drawdown over the past period was -21.41%, suggesting that a severe sell-off could take the stock down to around $212, a 21.6% drop from current levels.
FAQ
The key risks include: 1) Financial risk: thin net margin of 2.32% and a current ratio of 0.85, which could strain liquidity if working capital swings persist; 2) Competitive risk: Evernorth faces pressure from UnitedHealth's Optum and CVS Caremark, and any major contract loss (e.g., Department of Defense) would be damaging; 3) Regulatory risk: potential legislation on PBM pricing could compress margins; 4) Macro risk: low beta (0.317) reduces market correlation but also limits upside in bull markets. The most severe risk is a combination of regulatory intervention and margin compression, which could drive the stock to its 52-week low of $239.51.
The 12-month forecast is based on three scenarios: bull case (25% probability) targets $342–$400, assuming successful strategic execution and multiple expansion; base case (55% probability) targets $288–$342, assuming steady growth and stable margins; bear case (20% probability) targets $239–$288, assuming regulatory headwinds and earnings misses. The base case is most likely, with the stock expected to trade up to the analyst average target of $342.29 as earnings grow in line with estimates. The key assumption is that revenue grows 6% YoY and operating margin stabilizes around 3.7–4.0%.
CI appears undervalued on most metrics. Its trailing PE of 12.34 and forward PE of 8.08 are well below the S&P 500 average and near the low end of its historical range (10–33). The PEG ratio of 0.15 suggests the market is pricing in minimal growth despite a 6.6% YoY revenue increase. The PS ratio of 0.27 is also near historical lows, and the EV/EBITDA of 8.36 is modest. However, the discount may be justified by thin net margins (2.32%) and regulatory risks. Compared to peers, CI trades at a discount, but the market is demanding a higher risk premium due to structural challenges in the PBM industry.
CI may be a good buy for value-oriented investors with a medium-term horizon, given its forward PE of 8.08 and 26.5% upside to the average analyst target of $342.29. The stock offers a 2.20% dividend yield and trades at a discount to its historical PE range of 10–33. However, the bear case is supported by an 8.91% one-year decline and recent analyst downgrades, which suggest unresolved headwinds. The biggest downside risk is a retest of the 52-week low of $239.51, implying an 11.5% loss. Therefore, it is suitable for investors who can tolerate volatility and believe in the company's strategic pivot, but it is not a low-risk buy.
CI is more suitable for long-term investment (minimum 2–3 years) given its low beta of 0.317, dividend yield of 2.20%, and stable free cash flow of $9.11 billion. The stock is in a downtrend, so short-term trading carries high risk of further declines. Long-term investors can benefit from the valuation discount and potential mean reversion, but they must be patient as the strategic pivot plays out. Earnings visibility is moderate, with analyst EPS estimates of $46.74 for the upcoming year. A suggested minimum holding period is 2 years to allow for margin stabilization and multiple expansion.